News
ALT
2.610
+0.38%
0.010
Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Altimmune (ALT)
TipRanks · 2d ago
Altimmune management to meet with Truist
TipRanks · 2d ago
Weekly Report: what happened at ALT last week (0928-1002)?
Weekly Report · 6d ago
Altimmune Appoints Richard Menziuso as Principal Accounting Officer
TipRanks · 09/29 11:29
Weekly Report: what happened at ALT last week (0921-0925)?
Weekly Report · 09/28 09:03
Altimmune’s Phase 3 MASH Trial Puts Pemvidutide in the Spotlight for Investors
TipRanks · 09/23 16:30
Altimmune Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 09/23 13:22
Altimmune Price Target Cut to $17.00/Share From $18.00 by Evercore ISI Group
Dow Jones · 09/23 13:22
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17
Benzinga · 09/23 13:11
Altimmune price target lowered to $17 from $18 at Evercore ISI
TipRanks · 09/23 12:00
Altimmune to Participate in Stifel Cardiometabolic Forum
Barchart · 09/23 07:00
Weekly Report: what happened at ALT last week (0914-0918)?
Weekly Report · 09/21 09:03
Weekly Report: what happened at ALT last week (0907-0911)?
Weekly Report · 09/14 09:04
Weekly Report: what happened at ALT last week (0831-0904)?
Weekly Report · 09/07 09:03
Weekly Report: what happened at ALT last week (0824-0828)?
Weekly Report · 08/31 09:04
Weekly Report: what happened at ALT last week (0817-0821)?
Weekly Report · 08/24 09:04
Altimmune Charts Long Runway with Bold Trial Push
TipRanks · 08/24 00:15
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
NASDAQ · 08/19 14:55
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
NASDAQ · 08/19 14:54
Altimmune Maintained at Buy as Late-Stage Liver Programs Advance and $20 Price Target Remains Unchanged
TipRanks · 08/17 11:37
More
Webull provides a variety of real-time ALT stock news. You can receive the latest news about Altimmune through multiple platforms. This information may help you make smarter investment decisions.
About ALT
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.